All In Biotech

Drug Trial Radar · NCT04457869

A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)

A Phase 2, Open-label, Single-arm, Multicenter Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

43

Planned (sponsor's estimate)

Start

Nov 1, 2020

Primary completion

Jul 31, 2022

Study completion Jan 1, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is a multi-center, prospective, open-label, two-stage optimized design, single-arm, phase II clinical study to evaluate the efficacy and safety of F520 for the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL).

Conditions

  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma

Interventions

  • F520Drug

    3mg/kg every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR) by Independent Review Committee (IRC) Independent Review Committee (IRC).Time frame: Approximately 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.